2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Factor Xa

Factor Xa

Xa

Fxa

Factor Xa

Related Products

PDF 0.5 MB

Factor Xa, a trypsin-like serine protease, is situated at the critical juncture between the intrinsic and extrinsic pathways, catalyzing the conversion of prothrombin to thrombin, and hence plays a pivotal role in the final common pathway of the cascade and has become an important target in the discovery and development of new anticoagulants. Factor Xa is a key protease of the coagulation pathway whose activity is known to be in part modulated by binding to factor Va and sodium ions.

Blood coagulation involves a complex cascade of enzymatic reactions, ultimately generating fibrin, the basis of all blood clots. This cascade is comprised of two arms, the intrinsic and extrinsic pathways which converge at factor Xa to form the common pathway. Factor Xa activates prothrombin to thrombin, which in turn catalyzes the conversion of fibrinogen to fibrin.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W145053
    ChloraMine-T hydrate
    		Inhibitor
    ChloraMine-T hydrate (Sodium chloro(4-methylbenzenesulfonyl)azanide (hydrate)) is a common reagent in various synthetic processes. It has been used as a reagent in aminohydroxylation and allylic amination reactions, a nitrogen source in aziridination reactions of alkenes and alkenes, and deprotection of sulfur groups in sulfur-containing compounds. It has been used as a reagent in the synthesis of factor Xa inhibitors. ChloraMine-T hydrate (Sodium chloro(4-methylbenzenesulfonyl)azanide (hydrate)) (0.2% w/v) is also an antimicrobial agent that kills Staphylococcus epidermidis, Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Proteus mirabilis, and Enterococcus cloacae.
    ChloraMine-T hydrate
  • HY-105240
    Delparantag
    		Inhibitor
    Delparantag (PMX-60056) is a salicylamide derivative and an effective unfractionated heparin (UFH) and low molecular weight heparin (LMWH) reversing agent. Delparantag shows ability to neutralize the anticoagulation and bleeding effects of UFH and LMWH.
    Delparantag
  • HY-153836A
    Anivamersen sodium
    		Inhibitor
    Anivamersen sodium is an RNA aptamer to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide.
    Anivamersen sodium
  • HY-18660S
    Ciraparantag-d8 tetrahydrochloride diacetate
    		Inhibitor
    Ciraparantag-d8 tetrahydrochloride diacetate (PER977-d8 tetrahydrochloride diacetate) is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
    Ciraparantag-d<sub>8</sub> tetrahydrochloride diacetate
  • HY-W854549
    Heparin pentasaccharide
    		Inhibitor
    Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events.
    Heparin pentasaccharide
  • HY-76409
    Otamixaban hydrochloride
    		Inhibitor 98.50%
    Otamixaban (FXV673) is a potent, selective, rapid-acting, competitive, and reversible fXa inhibitor (Ki=0.5 nM) that effectively inhibits both free and prothrombinase-bound fXa.
    Otamixaban hydrochloride
  • HY-100652A
    O-Desmethyl apixaban sulfate sodium
    		Inhibitor
    O-Desmethyl apixaban sulfate sodium is a major circulating metabolite of Apixaban in humans. O-Desmethyl apixaban sulfate sodium inhibits factor X (FXa) with a Ki of 58 μM.
    O-Desmethyl apixaban sulfate sodium
  • HY-122592
    Zifaxaban
    		Inhibitor
    Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC50 of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research.
    Zifaxaban
  • HY-125856A
    Milvexian TFA
    		Inhibitor
    Milvexian TFA (BMS-986177 TFA) is a factor XIa inhibitor with biological activity to prevent venous thromboembolism. Milvexian TFA was effective in reducing the occurrence of venous thromboembolism in patients undergoing knee replacement surgery. Milvexian TFA has good selectivity and shows significant inhibitory effects on plasma kallikrein and trypsin. Milvexian TFA has a bioavailability of 32%, which means it has a high absorption rate in the body. Milvexian TFA showed a relatively low risk of bleeding in clinical trials.
    Milvexian TFA
  • HY-12631
    BMS-654457
    		Inhibitor
    BMS-654457 is a small-molecule, reversible inhibitor of factor XIa (FXIa), binding with human and rabbit FXIa with Kis of 0.2 and 0.42 nM, respectively.
    BMS-654457
  • HY-144658
    FXIa-IN-8
    		Inhibitor
    FXIa-IN-8 is a potent and selective FXIa inhibitor with an IC50 of 14.2 nM. FXIa-IN-8 shows antithrombotic activity without increasing the bleeding risk and obvious toxicitysup>[1].
    FXIa-IN-8
  • HY-153835
    Pegnivacogin
    		Inhibitor
    Pegnivacogin is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.
    Pegnivacogin
  • HY-126809
    Chromozym PK
    Chromozym PK is a Chromogenic Substrate and can be used in Factor XII assay.
    Chromozym PK
  • HY-19373
    RWJ-445167
    		Inhibitor
    RWJ-445167 (3DP-10017) is a dual inhibitor of thrombin and factor Xa with Ki of 4.0 nM and 230 nM, respectively, exhibiting potent antithrombotic activity.
    RWJ-445167
  • HY-18660A
    Ciraparantag TFA
    		Inhibitor
    Ciraparantag TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban.
    Ciraparantag TFA
  • HY-P10860
    cMCoFx1
    		Inhibitor
    cMCoFx1 is a potent and selective FXIIa cyclic peptide inhibitor. cMCoFx1 has high binding affinity (KD: 900 pM) and inhibitory activity (Ki: 370 pM) for FXIIa. cMCoFx1 can effectively inhibit endogenous clotting pathways, and cMCoFx1 is stable in serum and non-cytotoxic.
    cMCoFx1
  • HY-P3009B
    Porcine Factor Xa
    Porcine Factor Xa is prepared by activating purified Porcine Factor X with Russells' Viper Venom, after which the Russells' Viper Venom is removed.
    Porcine Factor Xa
  • HY-P3126
    Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride
    		98.00%
    Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride is a factor Xa specific chromogenic substrate.
    Suc-Ile-Glu(γ-pip)-Gly-Arg-pNA hydrochloride
  • HY-E70553
    Human Protein Z
    Human Protein Z is a 62 kDa vitamin K-dependent plasma protein that serves as a cofactor for the inhibition of factor Xa by protein Z-dependent protease inhibitor (ZPI).
    Human Protein Z
  • HY-107966
    Heparin calcium (MW 15000-19000)
    		Inhibitor
    Heparin calcium (MW 15000-19000) is an anticoagulant which binds reversibly to antithrombin III (ATIII) to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors IX, X, XI, and XII and prevents the transformation of fibrinogen to fibrin.
    Heparin calcium (MW 15000-19000)
Cat. No. Product Name / Synonyms Application Reactivity